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Host response to RNA virus infection is sensed by
RNA sensors such as RIG-I, which induces MAVS-
mediated NF-kB and IRF3 activation to promote in-
flammatory and antiviral responses, respectively.
Here, we have found that CARMA3, a scaffold protein
previously shown to mediate NF-kB activation
induced by GPCR and EGFR, positively regulates
MAVS-induced NF-kB activation. However, our
data suggest that CARMA3 sequesters MAVS from
forming high-molecular-weight aggregates, thereby
suppressing TBK1/IRF3 activation. Interestingly,
following NF-kB activation upon virus infection,
CARMA3 is targeted for proteasome-dependent
degradation, which releases MAVS to activate IRF3.
When challenged with vesicular stomatitis virus or
influenza A virus, CARMA3-deficient mice showed
reduced disease symptoms compared to those of
wild-type mice as a result of less inflammation and
a stronger ability to clear infected virus. Altogether,
our results reveal the role of CARMA3 in regulating
the balance of host antiviral and pro-inflammatory re-
sponses against RNA virus infection.
INTRODUCTION
The innate immune system is the first line of host defense against
infection, which is essential for initial detection and recognition of
pathogens, activation of acute anti-microbial responses, and
subsequent activation of adaptive immunity. This system utilizes
pattern recognition receptors such as Toll-like receptors (TLRs)
on the cell surface and cytosolic retinoic acid-inducible gene 1
(RIG-I)-like receptors (RLRs) to detect the invading pathogenCell(Baum and Garcı´a-Sastre, 2011; Janeway, 2013; Jiang et al.,
2011a). The RLR family of proteins is crucial for detecting viral
RNA in cytosol. It is composed of RIG-I, melanoma differentia-
tion-associated protein 5 (MDA5), and laboratory of genetics
and physiology 2 (LGP2). RIG-I senses 50-triphosphate RNA as
well as short (<2-kb) double-stranded RNA (dsRNA) and is
essential for innate immunity to many single-stranded RNA
(ssRNA) viruses, including influenza A virus (IAV), Sendai virus
(SeV), respiratory syncytial virus (RSV), vesicular stomatitis virus
(VSV), etc. In contrast, MDA5 recognizes longer dsRNA (>2 kb)
and protects the host from infection of encephalomyocarditis vi-
rus (EMCV), Theiler’s virus, mengovirus, murine norovirus, and
murine hepatitis virus (Kato et al., 2006; McCartney et al.,
2008; Roth-Cross et al., 2008).
Without stimulation, RIG-I is in the closed conformation with
the N-terminal CARD domains bound to the central helicase
domain. Upon binding of the CTD to viral RNA, RIG-I undergoes
conformational changes, oligomerization, and exposure of the
CARD domains to recruit a signaling adaptor called mitochon-
drial antiviral-signaling protein (MAVS). MAVS contains an N-ter-
minal CARDdomain, a proline-rich region, and a transmembrane
domain (TMD) at the C terminus. The CARD domain is important
for its interaction with upstream RLRs (Goubau et al., 2014; Ka-
wai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al.,
2005). The proline-rich region is required for the recruitment of
multiple E3 ligases, such as tumor necrosis factor (TNF) receptor
(TNFR)-associated factors (TRAFs). The TMD domain is key for
MAVS localization at the mitochondrial outer membrane. Upon
activation, MAVS forms a functional prion-like structure at mito-
chondria and works as a platform to form a MAVS signalosome
that further activates IKKa/IKKb/NEMO signaling and TBK1/
IKKε/NEMO signaling (Liu et al., 2013).
Activation of IKKa/IKKb/NEMO triggers activation of transcrip-
tion factor necrosis factor kB (NF-kB) and, thus, induction of pro-
inflammatory cytokines (Liu and Gu, 2011). These cytokines are
important to induce inflammatory responses and to restrict viralReports 14, 2389–2401, March 15, 2016 ª2016 The Authors 2389
replication and spread (Dienz et al., 2012). Elevated levels of pro-
inflammatory cytokines are closely correlated with severity of
clinical diseases, including airway inflammation and acute lung
injury during influenza infection in children (Chiaretti et al.,
2013). On the other hand, activation of the TBK1/IKKε/NEMO
complex leads to activation of IRF3 and production type I inter-
ferons (IFNs), including IFNa and IFNb (Fitzgerald et al., 2003;
Sankar et al., 2006; Zhong et al., 2008). Type I IFNs are potent in-
ducers for the expression of hundreds of IFN-stimulated genes
(ISGs) in paracrine and autocrine fashions, which induce a
cellular antiviral state on the target cells (Au et al., 1995; Schafer
et al., 1998; Sun et al., 2010). Recent mechanistic studies have
found that, upon activation, MAVS forms a prion-like fibril at
mitochondria and acts as an active platform for the recruitment
of E3 ligases, including TRAF6, TRAF2, and TRAF5, through
distinct TRAF-binding domains (Hou et al., 2011; Liu et al.,
2013; Xu et al., 2014). These E3 ligases are essential for signaling
downstream of MAVS, regulating the polyubiquitination chains,
and recruiting downstream IKKa/IKKb/NEMO complex and
TBK1/IKKε/NEMO complex (Liu et al., 2013).
It has been an important question why different individuals
display highly variable systemic symptoms across the infected
populations during outbreaks of seasonal virus infection. To
study how genetic polymorphisms contribute to this variation,
Ferris et al. (2013) crossed different incipient lines of mice, which
exhibit a broad range of susceptibility to IAV infection, and iden-
tified three novel quantitative trait loci (QTLs) that may contribute
to the susceptibility for IAV infection. One of these QTLs, Hrl4,
contains 13 genes (Ferris et al., 2013). Among these genes,
most of them do not have a clear link to the antivirus response
except for the CARD10 gene (Ferris et al., 2013), which encodes
a scaffold protein named CARMA3 (Jiang and Lin, 2012).
CARMA3 contains multiple protein-protein interaction do-
mains, including an N-terminal CARD domain, a coiled-coil
domain, and a C-terminal MAGUK domain (Gaide et al., 2001;
Jiang and Lin, 2012). CARMA3 is expressed only in non-hemato-
poietic cells, while CARMA1, a related protein, is expressed only
in hematopoietic cells. The CARMA proteins share similar struc-
ture and functions, albeit with distinct tissue distribution. Upon
activation, CARMA proteins form a complex with B cell lym-
phoma 10 (BCL10) and caspase-like proteinmucosa-associated
lymphoid tissue lymphoma translocation protein 1 (MALT1), and
theCARMA-BCL10-MALT1 (CBM) complex functions to activate
the downstream IKK complex, leading to activation of NF-kB
(Jiang and Lin, 2012). Previous studies have shown that
CARMA3 is crucial in mediating G protein-coupled receptor
(GPCR)- and epidermal growth factor receptor (EGFR)-, but
not TLR- or TNFR-, induced NF-kB activation (Grabiner et al.,
2007; Jiang et al., 2011b; Klemm et al., 2007; McAllister-Lucas
et al., 2007). However, it is unknown whether CARMA3 also is
involved in regulating the host responses to viral infection.
It is known that virus infection induces robust NF-kB activation
in host cells to trigger expression of pro-inflammatory cytokines,
which help to inhibit virus replication and spread in the host.
Since CARMA3 is located in the genomic locus that contributes
to host’s susceptibility to viral infection and is involved in NF-kB
signaling, we investigated its role in host antiviral response. Our
data suggest that CARMA3 contributes to inflammatory and2390 Cell Reports 14, 2389–2401, March 15, 2016 ª2016 The Authorantiviral responses via regulating RIG-I/MAVS-induced TBK1/
IRF3 and NF-kB activation. We have found that CARMA3 defi-
ciency resulted in the defect in VSV- and RNA-induced NF-kB
activation and production of pro-inflammatory cytokines, but,
surprisingly, enhanced TBK1/IRF3 activation and production of
type I IFN, thereby displaying a reduced viral load in VSV-in-
fected cells and tissues. Mechanistic studies showed that
CARMA3 inhibited IRF3 activation through blocking the forma-
tion of MAVS aggregation. Together, these results reveal that
CARMA3 is a key molecule that regulates the balance between
RNA virus infection-induced inflammatory and antiviral innate
immune response.
RESULTS
CARMA3Negatively RegulatesHost Antiviral Responses
Recent genetic studies indicate that theCARD10 gene is located
in the genomic locus that may contribute to the host’s suscepti-
bility to IAV infection (Ferris et al., 2013). To explore the biological
significance of CARMA3 in host antiviral response, we chal-
lenged wild-type (WT) and CARMA3/ (knockout [KO]) mice
with IAV strain PR8, a strain that has been highly adapted in
mice and causes disease symptoms and mortality in mice. IAV
infection caused a significant body weight loss of WT mice, but
not that of CARMA3 KO mice (Figure 1A). Viral yield was much
higher in lungs of WT mice than in those of CARMA3 KO mice
at 2 days post-infection (dpi) (Figure 1B). Similarly, lung injury
caused by IAV infection was greatly attenuated in CARMA3 KO
mice (Figure S1A), suggesting that CARMA3 plays a negative
role in antiviral response against IAV infection. Consistently, we
found that CARMA3 KO mice produced more type I IFN IFNb
in lungs compared to WT mice (Figure 1C), but expressed less
pro-inflammatory cytokines IL-6, IL-1a, and IL-1b following IAV
infection (Figures 1D and S1B–S1D), suggesting that CARMA3
also plays a positive role in inflammation in response to influenza
virus infection.
VSV is another negative sense, ssRNA virus, and its infection
induces a flu-like symptom like IAV does. To examine whether
CARMA3 also contributes to the host responses to VSV infec-
tion, we challenged WT and CARMA3 KO mice intranasally
with VSV. Since VSV is a neurotropic virus and brain is one of pri-
mary targeting tissues of VSV, we examined the viral load in brain
of these mice. Interestingly, we found that viral loads were signif-
icantly higher in the olfactory bulbs (OBs) of the brain in WTmice
than those in CARMA3 KO mice (Figures 1E and 1F), although
smaller differences were found in spleen and lung of these
mice (Figures S1E and S1F). Consistent with the low viral load
in CARMA3KOmice, we found that CARMA3KOmice produced
significantly higher levels of local IFNb in OBs (Figure 1G),
whereas the expressions of IFNg and G-CSF in the brain of WT
and CARMA3 KO mice were similar (Figures S1G and S1H).
Similar to the response to IAV infection, we found that production
of pro-inflammatory cytokines, such as IL-6, IL-1a, IL-1b, and
TNF-a, in the sera of CARMA3 KO mice was significantly
reduced compared to WT mice 2 days following VSV infection
(Figures S1I–S1M). Together, these results further support the
above observations that CARMA3 plays a negative role in regu-
lating antiviral responses in the host, but it plays a positive role ins
Figure 1. CARMA3 Plays Negative Roles in
Antiviral Response to Influenza/VSV Infec-
tion In Vivo
(A) The 6- to 8-week-old CARMA3 WT and KO
mice (n R 5 per group) were intranasally inocu-
lated with 600 PFUs of IAV per mouse. The weight
loss was monitored daily for 14 days and plotted.
(B–D) Mice were infected as in (A). At 2 dpi, mouse
lungs were harvested. (B) Viral loads were tittered
and plotted. (C) At 4 dpi, lungs were harvested and
cytokine production in mRNA level was measured
by real-time qPCR. (D) At 4 dpi, lung fluid was
harvested and cytokine production was measured
by ELISA essay.
(E–G) The 6- to 8-week-old CARMA3 WT and KO
mice (n R 5 per group) were intranasally inocu-
lated with 107 PFUs of VSV-GFP per mouse. (E) At
2 dpi, olfactory bulbs (OBs) were harvested and
imaged. (F) Viral loads in OBs were tittered and
plotted in log scale. (G) At 1 dpi, OBs were har-
vested and cytokine production inmRNA level was
measured by qPCR. The p values were generated
by Student’s t test.regulating the expression of pro-inflammatory cytokines in
response to viral infection.
CARMA3 Regulates RIG-I/MAVS-Mediated IKK/NF-kB
Activation In Vitro
SinceCARMA3 is only expressed in non-hematopoietic cells, the
observed effect of CARMA3 deficiency on viral infection in vivo
might be compromised by the contribution of hematopoietic
cells. To reveal the molecular mechanism by which CARMA3 af-
fects inflammatory and antiviral responses to virus infection, we
prepared primary WT and CARMA3 KO mouse embryonic
fibroblast (MEF) cells and stimulated these cells with VSV.
Consistent with the in vivo data, we found that VSV infection in
WT MEF cells induced significantly higher levels of IL-6 mRNA
and protein than those in CARMA3 KO MEF cells (Figures 2A
and 2B). Since IL-6 is a well-known target of NF-kB, weCell Reports 14, 2389–2401examined the NF-kB activation and found
that NF-kB activation was partially defec-
tive in CARMA3 KO MEF cells following
VSV stimulation (Figure 2C).
It has been shown that dsRNA virus
infection can induce NF-kB through both
TLR signaling and RIG-I/MAVS signaling.
Given the fact that CARMA3 is not
required for TLR-induced NF-kB activa-
tion (Grabiner et al., 2007), we hypothe-
sized that CARMA3 only mediates RIG-I/
MAVS-induced NF-kB, which can explain
why VSV-induced NF-kB was only partial
defective in CARMA3 KO cells. To test
this hypothesis, we stimulated WT and
CARMA3 KO MEF cells with RIG-I-spe-
cific ligands poly(I:C) or 50 triphosphate
dsRNA (50ppp-dsRNA). Consistently, we
found that NF-kB activation and produc-tion of IL-6 were severely defective in CARMA3 KO MEF cells
in response to these stimuli (Figures 2D–2F, S2A, and S2B).
Furthermore, we immortalized CARMA3 WT and KO MEF cells
and reconstituted the KO cells with HA-tagged CARMA3 to its
endogenous level (Figure S2C). This reconstitution of CARMA3
rescued the phenotypes (Figures 2G–2J). To find out if this is
also the case in other cell types, we used BEAS-2B cells, a pri-
mary and immortalized human lung epithelial cell line, with
knockdown of CARMA3 expression via small hairpin RNA
(shRNA) (Figure S2D), and consistent data were observed (Fig-
ures 2K and 2L).
CARMA3 Regulates RIG-I/MAVS-Mediated TBK1/
IRF3-IRF7 Activation In Vitro
Type I IFNs such as IFNa and IFNb are important antiviral
cytokines that are induced by RIG-I/MAVS-mediated activation, March 15, 2016 ª2016 The Authors 2391
Figure 2. CARMA3 Plays a Positive Role in Pro-inflammatory Response to RNA Virus Infection
(A–F) Primary CARMA3WT and KOMEF cells were infected with VSV atMOI = 3 (A–C) or transfected with poly(I:C) (D–F) for the indicated time. (A and D) RNAwas
isolated and cytokine production in mRNA level was measured by real-time qPCR, normalized to the internal control GAPDH. (B and E) Cytokine production in
culture supernatants was measured by ELISA assay. (C and F) Nuclear fractions were isolated and electrophoretic mobility shift assay (EMSA) analysis was
performed to check NF-kB activation. Oct-1 served as an internal control.
(G–J) E1A-immortalized CARMA KOMEF cells were generated and reconstituted with HA-tagged CARMA3 or vector as indicated. These cells were infected with
VSV atMOI = 3 (G andH) or transfected with poly(I:C) (I and J) for the indicated time. (G and I) Cytokine production in culture supernatants wasmeasured by ELISA
assay. (H and J) Nuclear fractions were isolated and EMSA analysis was performed to check NF-kB activation. Oct-1 served as an internal control.
(K and L) BEAS-2B cells with stable knockdown by shRNA against CARMA3 or control were established and infected with VSV at MOI = 3 for the indicated time.
(K) Nuclear fractions were isolated and EMSA analysis was performed to check NF-kB activation. Oct-1 serves as an internal control. (L) RNA was isolated and
cytokine production in mRNA level was measured by real-time qPCR, normalized to the internal control GAPDH.of TBK1-IRF3 signaling. We found that VSV infection induced
significantly higher levels of IFNbmRNA and protein in CARMA3
KOMEF cells than in WT MEF cells (Figures 3A and 3B). Consis-
tently, IRF3 phosphorylation at S396 and TBK1 phosphorylation
were induced at higher levels in CARMA3 KO MEF cells at 6 and
8 hr following VSV infection (Figure 3C). To determine if this
observation is specific for viral infection, we stimulated these
cells with RIG-I-specific ligands, 50triphosphate dsRNA (50ppp-
dsRNA), or poly(I:C). Consistently, production of IFN and IRF3
activation were enhanced in CARMA3 KO MEF cells (Figures
3D–3F and S3A–S3E). Furthermore, the virus load was reduced
in CARMA3 KO MEF cells compared to that in WT MEF cells
(Figure 3G).
To further confirm the above data, we reconstituted CARMA3
KO MEF cells with either a CARMA3 expression plasmid or a
control vector. We found that the phenotypes observed in
CARMA3 KO MEFs were reverted in CARMA3-reconstituted2392 Cell Reports 14, 2389–2401, March 15, 2016 ª2016 The AuthorKO MEF cells (Figures 3H–3K). Consistently, knockdown of
CARMA3 in human lung epithelial cells (BEAS-2B) rendered
stronger TBK1/IRF3 phosphorylation and the higher expression
level of type I IFN following VSV infection (Figures 3L, 3M, and
S3F). Furthermore, we isolated primary lung cells from CARMA3
WT and KOmice, and higher IFNb was detected in the CARMA3
KO lung cells compared to that inWT cells (Figure S3G), although
we were not able to detect any significant difference in IL-6
production, which likely was due to the high basal level of IL-6
production in these cells (Figure S3H).
BCL10 Regulates RIG-I/MAVS-Mediated NF-kB and IRF3
Activation In Vitro
Previous studies have shown that BCL10 and MALT1 bind to
CARMA3 to form the CBM complex upon EGFR- and GPCR-
induced NF-kB activation (Grabiner et al., 2007; Jiang et al.,
2011b; Klemm et al., 2007; McAllister-Lucas et al., 2007; Wangs
Figure 3. CARMA3 Plays a Negative Role in Antiviral Response to RNA Virus Infection
(A–G) Primary CARMA3WT andKOMEF cells were infectedwith VSV atMOI = 3 (A–C, G, and H) or transfectedwith poly(I:C) (D–F) for the indicated time. (A andD)
RNA was isolated and cytokine production in mRNA level was measured by real-time qPCR, normalized to the internal control GAPDH. (B and E) Cytokine
production in culture supernatants was measured by ELISA analysis. (C and F) Results from western blotting are shown. (G) Viral load in the supernatants of
primary MEF cells infected with VSV at MOI = 3 for 12 hr were tittered and plotted.
(H–K) E1A-immortalized CARMA KOMEF cells with the reconstitution of HA-tagged CARMA3 or vector were infected with VSV at MOI = 3 (H and I) or transfected
with poly(I:C) (J and K) for the indicated time. (H and J) Cytokine production in culture supernatants wasmeasured by ELISA assay. (I and K) Results fromwestern
blotting are shown.
(L and M) BEAS-2B cells with stable knockdown by shRNA against CARMA3 or control were established and infected with VSV at MOI = 3 for the indicated time.
(L) Results from western blotting are shown. (M) RNA was isolated and cytokine production in mRNA level was measured by real-time qPCR, normalized to the
internal control GAPDH.et al., 2007a). Next wewanted to determine if BCL10 andMALT1
play a similar function as CARMA3 in response to virus infection.
Similar to CARMA3 deficiency, BCL10 deficiency led to reduced
expression of IL-6 but enhanced expression of IFNb and a higher
level of IRF3 phosphorylated upon VSV infection or poly(I:C)
treatment in primary MEF cells (Figures 4A–4E). Consistently,
we observed reduced viral load in OBs of BCL10 KO
mice compared to WT mice (Figure 4F). These results indicate
that BCL10 plays a similar role as CARMA3 in response to virus
infection.
However, MALT1 deficiency did not result in defective IL-6
production (Figure S4A). Although IFNb expression was slightly
increased in MALT1 KOMEF cells (Figure S4B), IFNa expression
was similar to that in WT MEF cells (Figures S4C and S4D).
Consistently, viral infection-induced NF-kB activation was not
significantly changed in MALT1 KO MEF cells (Figure S4E).
Although IRF3 phosphorylation was slightly enhanced inCellMALT1 KO MEF cells (Figure S4F), it was not as significant as
what we observed in CARMA3 KO or BCL10 KO MEF cells.
Together, these data suggest that MALT1 does not play a domi-
nant role in regulating viral infection-induced NF-kB and IRF3
activation.
CARMA3 Regulates RIG-I/MAVS-Mediated IKK/NF-kB
Activation and TBK1/IRF3 Activation in an Independent
Manner
Interestingly, we found that VSV infection-induced NF-kB acti-
vation could be detected as early as the first hour post-infec-
tion, whereas IRF3 phosphorylation was not detectable until
4 hr post-infection (Figures 2C and 3C). Since VSV infection-
induced NF-kB activation was partially defective but IRF3 acti-
vation was enhanced in CARMA3 KO MEF cells, we decided to
examine whether NF-kB-targeted genes expressed at early
time points post-infection might inhibit IRF3 activation. ToReports 14, 2389–2401, March 15, 2016 ª2016 The Authors 2393
Figure 4. BCL10 Plays a Positive Role in
Pro-inflammatory Response and a Negative
Role in Antiviral Response to VSV Infection
and Poly (I:C) Treatment
(A–E) Primary BCL10 WT and KO MEF cells were
infected with VSV at MOI = 3 (A–C) or transfected
with poly(I:C) (D and E) for the indicated time. (A,
B, D, and E) RNA was isolated and cytokine pro-
duction in mRNA level was measured by real-time
qPCR, normalized to the internal control GAPDH.
(C) The cells were harvested, lysed, and subjected
to western blotting analysis.
(F) The 6- to 8-week-old BCL10 WT and KO mice
(nR 5 per group) were intranasally inoculated with
107 PFUs of VSV-GFP per mouse. At 2 dpi, OBs
were harvested and viral loads in OBswere tittered
and plotted in log scale.test this possibility, WT MEF cells were pre-treated with NF-kB
nuclear translocation inhibitor (NF-kBi) for 1 hr before VSV
infection. Although NF-kBi pretreatment partially inhibited NF-
kB activation (Figure 5A), it did not enhance but instead partially
inhibited IRF3 phosphorylation (Figure 5B), indicating that it is
not NF-kB-inducing genes suppressing IRF3 phosphorylation.
To further support this conclusion, we transfected IkBa su-
per-repressor (SR) mutant into immortalized MEF cells, and
we found that, although expression of IkBa SR mutant could
suppress VSV-induced NF-kB activation, it could not enhance
IRF3 phosphorylation (Figures 5C and 5D). Finally, to determine
whether newly synthesized proteins regulate IRF3 activation,
primary MEF cells were pretreated with protein synthesis inhib-
itor cycloheximide (CHX) before poly(I:C) transfection. Pre-
treatment with CHX did not alter IRF3 activation (Figure 5E).
Therefore, the impaired NF-kB activation at early hours post-
infection is not the cause for the enhanced IRF3 activation in2394 Cell Reports 14, 2389–2401, March 15, 2016 ª2016 The AuthorsCARMA3 KO MEF cells, indicating that
CARMA3 regulates NF-kB and IRF3 acti-
vation through an independent event.
CARMA3 and BCL10 Regulate
RIG-I/MAVS Signaling by Binding
to MAVS
To determine the molecular mecha-
nism bywhich CARMA3 and BCL10 regu-
late viral infection-induced NF-kB and
IRF3 activation, CARMA3 or BCL10 was
knocked down by shRNA in HEK293T
cells. Overexpression of MAVS induced
robust expression of NF-kB-dependent
and IRF3-dependent luciferase reporters
in control cells, whereas defective NF-kB
activation and enhanced IRF3 activation
were observed in CARMA3 or BCL10
knockdown cells (Figures 5F, 5I, and
S5A). However, when TBK1 or IKKε was
overexpressed in these cells, knockdown
of CARMA3 or BCL10 did not alter activa-
tion of NF-kB or IRF3 (Figures 5G, 5H, 5J,5K, S5B, and S5C), indicating that CARMA3 and BCL10 function
downstream of MAVS but upstream of TBK1 and IKKε.
Since CARMA3 is a scaffold protein with multiple protein-pro-
tein interaction domains, we examined whether CARMA3 is
physically associated with MAVS. When overexpressed in
HEK293T cells, CARMA3 bound to MAVS but only weakly to
RIG-I (Figure 6A), whereas BCL10 interacted with both MAVS
and RIG-I (Figure S6A). In contrast, MALT1 could not bind to
MAVS when overexpressed in HEK293T cells (Figure S6B).
Furthermore, endogenous MAVS was capable of interacting
with overexpressed CARMA3 or BCL10 in HEK293T cells (Fig-
ure 6B). More interestingly, inducible interactions, but not consti-
tutive interactions, were observed between endogenous MAVS
and BCL10 or between endogenous MAVS and CARMA3 in
CARMA3-reconstituted KO MEF cells (Figures 6C and 6D). The
dynamic interaction between MAVS and CARMA3 could be de-
tected in both primary BCL10 Het and KO MEF cells (Figure 6E),
Figure 5. CARMA3 Functions Downstream
of MAVS but Upstream of TBK1 and IKKε
(A and B) Primary WT MEF cells were pretreated
with NF-kB translocation inhibitor (NF-kBi) for 1 hr
before VSV infection. Results from EMSA analysis
(A) and western blotting (B) are shown.
(C and D) E1A-immortalized CARMA3 KO cells
with reconstitution of CARMA3 were transfected
with IkBa super-repressor (SR) or vector control.
At 48 hr post-transfection, the cells were infected
with VSV for the indicated time. Results from
EMSA analysis (C) and western blotting (D) are
shown.
(E) Primary WT MEF cells were pretreated with
CHX for 1 hr before transfection with poly (I:C).
Results from western blotting are shown.
(F–K) HEK293T cells were stably knocked down
with shRNA against GFP, CARMA3 (C3), or BCL10
(B10). These cells were co-transfected with MAVS
(F and I), TBK1 (G and J), or IKKε (H and K) together
with IFNb-Luc and R-Luc (F, G, and H) or together
with NF-kB-Luc and R-Luc (I, J, and K). Luciferase
assay was performed at 18 hr post-transfection.
R-Luc activity served as the internal control.whereas the MAVS-BCL10 interaction could only be detected in
CARMA3 KO cells reconstituted with CARMA3, but not with its
vector control (Figure 6F). These data suggested that BCL10
might be recruited to the MAVS-containing complex via
CARMA3, but not vice versa. To address whether CARMA3
binds to MAVS through CARD-CARD interaction, we co-trans-
fected HEK293T cells with MAVS and CARMA3 WT or truncate
mutants (Figures S6C and S6D). We found that the C-terminal
GUK domain, but not the CARD domain, of CARMA3 appeared
to be critical for the binding to MAVS.
CARMA3 and BCL10 Regulate RIG-I/MAVS Signaling by
Disrupting MAVS Aggregation
It has been shown that infection with SeV, another negative, sin-
gle-stranded virus, induces the formation of large MAVS aggre-
gates, which is functionally important in mediating IRF3 activa-
tion (He et al., 2015; Hou et al., 2011; Moresco et al., 2011; Xu
et al., 2014). Since CARMA3 binds to MAVS, we hypothesized
that CARMA3 may block MAVS oligomerization. When CARMA3
was overexpressed together with RIG-I in HEK293T cells,
CARMA3 was detected in the mitochondrial fraction in a dose-
dependent manner (Figure 7A). In contrast, only a very smallCell Reports 14, 2389–2401fraction of RIG-I was isolated together
with mitochondria (Figure 7A). This sug-
gests that CARMA3 can be recruited to
mitochondria and bind to MAVS. Impor-
tantly, overexpression of CARMA3 was
able to disrupt the formation of endoge-
nous MAVS aggregates in semi-dena-
turing detergent agarose gel electropho-
resis (SDD-AGE) gel, which is 2% SDS
resistant (Figure 7A). This is also the
case for BCL10 (Figures S7A and S7B).
To further confirm that CARMA3 blocksMAVS from forming aggregates, we infected primary MEF cells
with VSV and isolated crude mitochondria. We observed signif-
icantly stronger formation of endogenous MAVS aggregates in
CARMA3 KO MEF cells at 6 hr post-infection (Figure 7B), and,
consistently, this stronger aggregation of MAVS in CARMA3
KO cells could be reverted when CARMA3 was reconstituted
back into the CARMA3 KO MEF cells (Figure 7C). Together,
these results indicate that CARMA3 plays a negative role in the
assembly of MAVS aggregates upon virus infection.
CARMA3 Is Targeted for Ubiquitination and Proteasome
Degradation
Due to the lack of anti-CARMA3 antibody suitable for detecting
endogenous CARMA3 protein by immunoblotting, we generated
stable cells that express HA-tagged CARMA3 in CARMA3 KO
MEF cells. Interestingly, we found that HA-tagged CARMA3 pro-
tein was gradually reduced upon VSV infection (Figures 7D–7G).
However, this reduction in CARMA3 protein was rescued by pre-
treatment of cells with proteasome inhibitor MG132 (Figures 7E
and 7F). This indicated that, following VSV infection, CARMA3
is targeted for proteasome degradation. Therefore, we per-
formed immunoprecipitaion with anti-HA agarose, and we found, March 15, 2016 ª2016 The Authors 2395
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Figure 6. CARMA3 Inducibly Interacts with MAVS and Functions to Interrupt the Interaction between MAVS and RIG-I
(A) HEK293T cells were transfected with HA-tagged CARMA3 alone (lane 1) or together with FLAG-tagged MAVS (lane 2) or FLAG-tagged RIG-I (lane 3). At 18 hr
post-transfection, the cells were lysed and the lysates were immunoprecipitated with anti-FLAG M2 agarose beads. The immunoprecipitates were subjected to
western blotting. The black solid arrows point to the band(s) of the protein as indicated.
(B) HEK293T cells were transfected with FLAG-tagged CARMA3 (lane 3) or FLAG-tagged BCL10 (lane 2) or together (lane 1). The lysates from lanes 2 and 3 were
immunoprecipitated with anti-FLAG M2 agarose beads. The lysates from lane 1 were immunoprecipitated with protein A agarose beads and served as the
negative control. The black solid arrows point to the band(s) of the protein as indicated.
(C and D) E1A-immortalized CARMA KO MEF cells with the reconstitution of HA-tagged CARMA3 were infected with VSV for the indicated time. The cells were
lysed and the lysates were immunoprecipitated with anti-BCL10 antibody or normal IgG control (C) or anti-HA antibody or normal IgG control (D). The immu-
noprecipitates were subjected to western blotting.
(E and F) Primary BCL10Het and KOMEF (E) or E1A-immortalized CARMAKOMEF (F) cells with the reconstitution of HA-taggedCARMA3 or vector were infected
with VSV for the indicated time. The cells were lysed and the lysates were immunoprecipitated with anti-CARMA3 antibody or IgG control (E) or anti-BCL10
antibody or IgG control (F). The immunoprecipitates were subjected to western blotting.
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Figure 7. CARMA3 Undergoes Signal-
Dependent Polyubiquitination and Degra-
dation
(A) HEK293T cells were transfected with RIG-I
alone (lanes 1 and 4) or together with FLAG-tagged
CARMA3 at the indicated dose (lanes 2–3 and
5–6). Crude mitochondria were isolated at 18 hr
post-transfection. Whole-cell lysates and lysates
from aliquots of mitochondria were subjected to
western blotting (upper panel). The rest of mito-
chondria lysates were subjected to SDD-AGE
analysis (bottom panel). The asterisk indicates
the CARMA3 protein band. Short and long in pa-
rentheses represent the short exposure or long
exposure, respectively.
(B and C) Primary CARMA3 WT and KO MEF cells
(B) or E1A-immortalized CARMA3 KO cells with
the reconstitution of CARMA3 or vector (C) were
infected with VSV for the indicated time. Crude
mitochondria were isolated and lysates from ali-
quots of mitochondria were subjected to western
blotting (bottom panel). The rest of the mitochon-
dria lysates were subjected to SDD-AGE analysis
(upper panel).
(D) E1A-immortalized CARMA3 KO MEF cells with
the reconstitution of HA-tagged CARMA3 or vec-
tors were infected with VSV for the indicated time.
The cells were lysed and the lysates were immu-
noprecipitated with anti-HA antibody. The immu-
noprecipitates were subjected to western blotting.
(E) E1A-immortalized CARMA3 KO cells with the
reconstitution of HA-tagged CARMA3 were pre-
treated with MG132 or CHX 1 hr before infection
with VSV as indicated. The cells were harvested at
6 hr post-infection, lysed, and subjected to west-
ern blotting.
(F) E1A-immortalized CARMA3 KO cells with the
reconstitution of HA-tagged CARMA3 were in-
fected with VSV for the indicated time. MG132 was
added to the sample in lane 4 at 2 hr post-infection.
The cells were lysed and the lysates were immu-
noprecipitated with anti-HA antibody (lanes 2–5) or
normal IgG control (lane 1). The immunoprecipi-
tates were subjected to western blotting.
(G) E1A-immortalized CARMA3 KO MEF cells with
the reconstitution of HA-tagged CARMA3 were
infected with VSV for the indicated time. The cells
were lysed and the lysates were subjected to
western blotting.that a high amount of K48-ubiquitinated CARMA3 was observed
in the presence of MG132 at 4 hr post-VSV infection (Figure 7F).
However, in contrast to CARMA3, the protein level of BCL10
was not significantly altered following VSV infection (Figure 7G).
Together, these results suggest that CARMA3 is targeted to pro-
teasome-mediated degradation following RNA virus infection.
DISCUSSION
In this study, we reveal that CARMA3 is a regulator of RIG-I/
MAVS signaling. We have found that CARMA3 regulates RIG-I/
MAVS-mediated NF-kB and TBK1/IRF3 activation in a two-
phase mechanism (Figure S7C). Upon RIG-I activation, MAVS
is first activated at early time points following viral infection,Cellwhich can activate IKKa/IKKb/NEMO in a CARMA3/BCL10-
dependent manner. However, in this early phase of post-infec-
tion, MAVS is sequestered by the CARMA3/BCL10 complex
via interaction, and, therefore, it cannot form the high-molecular
weight aggregates, which is required for downstream activation
of TBK1/IRF3 signaling. With time, CARMA3 is targeted to
a proteasome-mediated degradation, which releases MAVS
that forms the functional aggregates and activate TBK1/IRF3
signaling. Therefore, CARMA3 functions as a host factor to regu-
late the balance of the RIG-I/MAVS-induced two downstream
signaling pathways for antiviral innate immune response and
the pro-inflammatory response. On one hand, CARMA3 plays
a positive role in MAVS-induced NF-kB activation, leading to
the induction of pro-inflammatory cytokines, but, on the otherReports 14, 2389–2401, March 15, 2016 ª2016 The Authors 2397
hand, it plays a negative role in MAVS-induced TBK1/IRF3
activation and production of antiviral cytokines, type I IFNs (Fig-
ure S7C). However, the precise mechanism as to how CARMA3
is targeted for ubiquitination-based proteasome degradation re-
quires further investigation. In addition, it will be interesting to
see if CARMA3 plays a general effect in response to other RNA
viruses as well as DNA viruses that are typically not recognized
by cytoplasmic RLRs.
Different individuals display highly variable systemic symp-
toms in response to viral infection. However, host factors
contributing to this variability are largely unknown. Recent
studies suggest that the CARD10 gene, which encodes
CARMA3, is located in a genomic locus that contributes to the
host’s susceptibility to RNA virus, such as IAV infection (Ferris
et al., 2013). Our data, showing the distinct regulation of
CARMA3 in the pro-inflammatory response and the antiviral
response, suggest that CARMA3 may be a gene contributing
to the host’s susceptibility to viral infection. Therefore, it will be
important to find out whether CARMA3 protein expression
levels or particular CARMA3 polymorphisms exist in different hu-
man populations, which may explain the variable susceptibility
among different populations in response to virus infection.
CARMA3 is distinguished from many other mediators down-
stream of MAVS identified so far, which are either positive or
negative mediators for both NF-kB activation and IRF3 activa-
tion. These mediators include NEMO, TRAF6, A20, and CYLD
(Friedman et al., 2008; Liu et al., 2013; Maelfait et al., 2012; Par-
vatiyar et al., 2010; Saitoh et al., 2005; Zhao et al., 2007). In
contrast, CARMA3 deficiency led to reduced NF-kB activation
but an increase in IRF3 activation. CARD9 is structurally related
to CARMA3 and contains a CARD domain and a coiled-coil
domain, but no MAGUK domain. CARD9 is primarily expressed
in myeloid cells. In bone marrow-derived dendritic cells
(BMDCs), CARD9 deficiency resulted in defects in NF-kB activa-
tion and production of pro-inflammatory cytokines, including
IL-6 and IL-1b, in response to 50ppp dsRNA treatment; however,
it did not alter the production of type I IFN (Poeck et al., 2010).
In addition to CARD9, CARMA1 is expressed in myeloid cells.
It will be interesting to find out how CARMA1, the counterpart
of CARMA3 in hematopoietic cells, functions in mediating
RIG-I/MAVS signaling in myeloid cells. In contrast to CARMA1,
CARMA3, or CARD9, BCL10 is universally expressed. BCL10
functions similarly to CARD9 in BMDCs in response to 50ppp
dsRNA treatment, whereas, in primary MEF cells, it functions
similarly to CARMA3 upon VSV infection or poly(I:C) treatment.
This suggests that BCL10 may regulate RIG-I/MAVS signaling
in a cell-type-specific manner.
During RNA virus infection, NF-kB activation can be induced
through TLR-dependent and TLR-independent signaling path-
ways. It has been demonstrated that CARMA3 is not required
for TLR-induced NF-kB activation (Jiang et al., 2011b; Pan and
Lin, 2013). In this study, we found CARMA3 deficiency induced
only partial defects in NF-kB activation, suggesting that
CARMA3 may play an important role in TLR-independent
NF-kB activation, which is induced by RIG-I/MAVS signaling.
TLR-dependent NF-kB activation may play dominant roles in
the induction of local IL-6 production in non-hematopoietic cells
following RNA viral infection, which may explain why we do not2398 Cell Reports 14, 2389–2401, March 15, 2016 ª2016 The Authorobserve a significant effect of CARMA3 deficiency in local IL-6
mRNA production in OBs following VSV infection.
Virus infection-induced NF-kB activation promotes expres-
sion of pro-inflammatory cytokines and chemokine, which are
crucial to trigger inflammatory responses in the host. During viral
infection, it is important to keep the inflammatory response
under control to avoid severe tissue damage. Overly robust
NF-kB activation or inflammation can lead to severe health con-
sequences. For example, Ebola virus, a negative sense, single-
stranded virus, is a highly virulent pathogen that causes a
frequently lethal hemorrhagic fever syndrome, which is well
correlated with the high inflammatory response that is induced
in the host (Rasmussen et al., 2014). Therefore, it is important
to regulate inflammatory response to a safe level to prevent se-
vere tissue damage in such patients during viral infection.
CARMA3 deficiency leads to a reduced NF-kB activation and
production of pro-inflammatory cytokines. Challenging WT
mice with IAV induced a strong production of pro-inflammatory
cytokines, including IL-6, and severe inflammation, lung injury,
and significant weight loss, which were attenuated in CARMA3
KOmice, indicating that CARMA3 is a key molecule to regulating
inflammatory responses in the host and potentially a therapeutic
target.
Previous studies indicated that NF-kB activation contributes
to the production of type I IFN in response to viral infection (Ba-
sagoudanavar et al., 2011; Wang et al., 2010, 2007b). In this
study, instead of observing a compromised production of type
I IFN, we found an even higher production of type I IFN in
CARMA3 KO MEF cells. Therefore, the contribution of the
enhanced IRF3 activation in the absence of CARMA3 not only
counteracted the defect of NF-kB but also resulted in greater
overall production of IFNb. This indicates the importance of
CARMA3 for inhibiting the expression of type I IFN and antiviral
responses, suggesting that IRF3 activation plays a more domi-
nant role in the expression of type I IFN than NF-kB activation
in response to RNA virus infection.
In this study, we found that CARMA3 functions downstream of
MAVS and upstream of TBK1 or IKKε. As a scaffold protein,
CARMA3 interacts with MAVS and prevents the formation of
high-molecular weight MAVS aggregates, thereby blocking
IRF3 activation. It is interesting that CARMA3 is gradually turned
over following VSV infection, which may serve as a mechanism
to turn off NF-kB activation, and, meanwhile, it releases MAVS
to form functional aggregates to induce IRF3 activation. Further
studies are necessary to determine the molecular mechanism as
to how CARMA3 is targeted for K48 ubiquitination and degrada-
tion, and targeting CARMA3 for degradation may help to reduce
inflammation while enhancing the antiviral response. Therefore,
understanding this mechanism may provide molecular insights
for designing therapeutic agents for suppressing viral infection-
induced inflammation.EXPERIMENTAL PROCEDURES
Antibodies and Reagents
Antibodies against Flag (sc-807), IkBa (sc-371), IKKa (sc-7218), HA (sc-7392),
His (sc-803), BCL10 (sc-5611), Myc (sc-40), IRF3 (sc-9028), NEMO (sc-8330),
b-actin (sc-8432), and a-tubulin (sc8035) were purchased from Santa Cruzs
Biotechnology. Antibodies against p-IkBa (9246), p-IKKa/b (2681), Caspase 3
(9664), p-IRF3 (4947), p-TBK1 (5483), and TBK1 (3013) were from Cell
Signaling Technology. The rabbit polyclonal antibody against Carma3 was
homemade against the peptide VRGRILQEQARLVWVEC, matching to the C
terminus of human and mouse CARMA3. The anti-MAVS antibody was kindly
provided by Dr. Zhijian J. Chen (UT Southwestern). Oligonucleotide probes for
NF-kB (E3291) and OCT-1 (E3241) were purchased from Promega. TRIzol
(15596-026) and Superscript III First-Strand Synthesis system (18080051)
were obtained from Invitrogen and DNase I kits (10104159001) were pur-
chased from Roche Applied Science. Two times SYBR Green PCR Master
Mix was purchased from Applied Biosystems. Influenza A/PR/8/34(H1N1)
was purchased from Charles River Laboratories. NF-kBi and CHX were pur-
chased from Sigma.
Cells
Cells were grown in DMEM (HEK293T, BHK, and MEF) containing 10% fetal
bovine serum (FBS) at 37Cand5%CO2except forMEFcells,whichwere incu-
bated at 37C and 8.5% CO2. BEAS-2B cells were purchased from ATCC,
cultured with LHC-8 medium from Thermo Fisher in pre-coated culture dishes
with BSA (Fisher Scientific), Fibronectin, andCollagen I bovine (Thermo Fisher).
Expression Plasmids
FLAG-tagged human CARMA3 has been described previously (Sun and Lin,
2008). HA-tagged mouse CARMA3 was cloned into pcDNA3 vector. RIG-I,
MAVS, TBK1, IKKε, and IkBa SR plasmids were purchased from Addgene.
FLAG- or Myc-tagged BCL10 has been described previously (Blonska et al.,
2007); shRNA against CARMA3 and BCL10 were purchased from Sigma.
Real-Time qPCR and ELISA Assay
The real-time qPCR and ELISA assay were performed as recommended by the
manufacturer’s protocol.
Luciferase Reporter Assay
The luciferase assay was performed as described previously (Blonska et al.,
2005). Briefly, 293T cells were seeded in triplicates in 12-well plates and trans-
fected with 60 ng NF-kB-dependent luciferase (firefly) reporter plasmid and
6 ng EF1a promoter-dependent Renilla luciferase reporter together with
1.5 mg expression vectors for Carma3, TMEM43WT or mutants, or vector con-
trols. The transfected cells were cultured in DMEM containing 10% FBS for
16 hr. The cells were harvested and lysed. Luciferase activities in the cell
lysates were measured by dual-luciferase kit (Promega).
Immunoprecipitation and Immunoblotting
These experiments were performed as described previously (Blonska et al.,
2005). Briefly, 1–5 3 106 cells were seeded, starved for 16 hr, and stimulated
with various stimulators for the appropriate time. The cells were then lysed in a
buffer containing 50 mM HEPES (pH 7.4), 250 mM NaCl, 1% Nonidet P-40,
1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, and a protease inhibitor
mixture (Roche Diagnostics). The cell lysates were subjected to SDS-PAGE
and western blot or immunoprecipitated with appropriate specific antibodies.
The immunoprecipitates were washed with lysis buffer four times eluted with
23 SDS loading buffer. The samples were boiled and separated on 10%
SDS-PAGE and transferred to nitrocellulose membranes. Immunoblots were
incubated with specific primary antibodies followed by horseradish peroxi-
dase-conjugated secondary antibodies, and they were developed by the
enhanced chemiluminescencemethod according to themanufacturer’s proto-
col (Pierce).
Preparation of Nuclear Extracts and Electrophoretic Mobility Shift
Assay
These experiments were performed as described previously (Blonska et al.,
2005). Briefly, 1–5 3 106 cells were seeded, starved for 16 hr, and stimulated
with various stimulators for the appropriate time, and nuclear extracts were
prepared. Nuclear extracts (5–10 mg) were incubated with 32P-labeled probes
at room temperature for 15 min. The samples were separated on a native
Tris-Borate-EDTA polyacrylamide gel, which was dried at 80C for 1 hr, and
exposed to X-ray film.CellLentivirus Infection for shRNA Knockdown
Lentiviruses were packaged as described previously (Jiang et al., 2011b).
Briefly, HEK293T were co-transfected with shRNA and packaging vectors
encoding VSV-G and DVPR using the calcium precipitation method. At 48 hr
post-transfection, the supernatant was collected and applied to infect target
cells. The infected cells were selected by puromycin for 3–4 days before the
conduction of experiments.
Isolation of Crude Mitochondria
These experiments were performed as described previously (Hou et al., 2011).
Briefly, cells were washed with ice-cold PBS twice and harvested by spinning
at 6003 g for 5 min. The cells were swollen in hypotonic buffer (10 mM Tris-Cl
[pH 7.5], 10 mM KCl, 0.5 mM EGTA, 1.5 mM MgCl2, 1 mM PMSF, and 13
EDTA-free protease cocktail) for 2.5 min at 4C. The swollen cells were ho-
mogenized for 40 strokes at 4C and spun at 600 3 g for 5 min. The superna-
tant was transferred to a new tube and spun once more. The resulting super-
natant was spun to pellet the mitochondria. The mitochondria pellet was
resuspended in mitochondria-resuspending buffer (MRB) (20 mM HEPES-
KOH [pH 7.4], 0.5 mM EGTA, 1 mM PMSF, and 13 EDTA-free protease cock-
tail) containing 0.8 M sucrose and pelleted by spinning at 7,0003 g for 10 min.
The pellet was resuspended and spun as above. The resulting pellet was re-
suspended, spun at 10,0003 g for 10 min, and lysed in MRB buffer containing
2% CHAPs on ice for 15 min. The mitochondria lysates were mixed with 23
loading dye (13 TBE, 10% glycerol, 4% SDS, and 0.005% bromophenol
blue) containing no reduction reagents.
SDD-AGE
SDD-AGE was performed as described previously with minor modifications
(Halfmann and Lindquist, 2008). Briefly, 1.5% agarose gel containing 0.1%
SDS was prepared in 0.253 TAE buffer. The mitochondria lysates in 13
loading dye were loaded into the wells. After electrophoresis in the running
buffer (0.253 TAE and 0.1% SDS) for 7 hr with a constant voltage of 30 V at
room temperature, the gel was rinsed with water and transferred to Immobilon
membrane (Millipore) by butterfly transfer in 13 TBS (50 mM Tris.Cl [pH 7.5]
and 150 mM NaCl). The membrane was then blotted with specific antibody
as immunoblotting.
VSV and Influenza Virus Mice Model
BALB/c mice (6–8 weeks old, n R 5 per group) were intranasally inoculated
with 20 ml H1N1 influenza virus (PFUs = 600 per mice) in PBS under isofluor-
ane sedation. Survival and body weight changes were recorded daily for 14
dpi. Animals that showed signs of severe disease and weight loss >25% of
their initial body weight were considered moribund and were humanely sacri-
ficed. Lungs were harvested at 4 dpi. All animal experiments and procedures
were conducted under the protocol and were approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of Texas MD
Anderson Cancer Center. For the VSV mouse model, 6- to 8-week-old
BALB/c mice (n R 5 per group) were intranasally inoculated with 20 ml VSV
(plaque-forming units [PFUs] = 1 3 107 per mouse) in PBS under isofluorane
sedation. Mouse serum tissues (lung, brain, and spleen) were harvested
2 days after infection.
VSV Plaque Assay
The VSV plaque assay protocol was previously described. Briefly, cells were
infected with VSV (MOI = 3). At 1 hr post-infection, the cells were washed twice
with serum-free DMEM and replenished with complete medium. The superna-
tant was collected at different time points, diluted with serum-free DMEM, and
used to infect BHK cells. At 1 hr post-infection, medium from the BHK cells
was removed and replaced with complete medium containing 0.5% methyl-
cellulose (Sigma-Aldrich) for 24 to 48 hr. BHK cells were fixed in fixation solu-
tion and stained with crystal violet. Plaques were counted and titers were
calculated as PFU per milliliter. Triplicate experiments were performed, and
the averages of the virus titers were calculated.
Influenza TCID50 Assay
MDCKs were passed in high-glucose DMEM (10% FBS and 1% Pen-Strep) in
a T175 (a 1:12 pass dilution every other day) at 37C. Cells (2 3 104) wereReports 14, 2389–2401, March 15, 2016 ª2016 The Authors 2399
seeded in 96-well plates at the night before assay with 150 ml DMEM (FBS and
Pen-Strep). The morning of the next day, influenza samples were thawed on
ice and then homogenized, transfering a 600-ml sample into the first tube of
the dilution series and serially diluting 184 ml across the tubes. Once samples
were diluted across tubes, they were kept on ice and 100 ml sample was added
to empty wells. Samples were incubated at 37C for 1 hr and aspirated off.
Then 150 ml DMEM with typsin (1 mg/ml) was added. Samples were incubated
at 37C for 3 days. After the 3 days, the media were aspirated off and 200 ml
Crystal violet working stock (40 ml 1% Crystal Violet, 80 ml Methanol, and
300 ml H2O) was added. The working stock sat for 1 hr. Crystal violet was
removed and samples were rinsed with water.
Statistical Analysis
The statistical analysis was performed by Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2016.02.031.
AUTHOR CONTRIBUTIONS
Conceptualization, C.J., Z.Z., and X.L.; Investigation, C.J., Z.Z., Y.Q., S.Z.,
T.W., X.Z., W.H., and C.M.; Writing – Original Draft, C.J.; Writing – Review &
Editing, M.T.H., M.S.M., and X.L.; Funding Acquisition, M.T.H., M.S.M.,
and X.L.
ACKNOWLEDGMENTS
This work was partially supported by grants R01AI050848 and R01AI116722
from the NIH to X.L.
Received: July 17, 2015
Revised: November 29, 2015
Accepted: February 1, 2016
Published: March 3, 2016
REFERENCES
Au, W.C., Moore, P.A., Lowther, W., Juang, Y.T., and Pitha, P.M. (1995). Iden-
tification of a member of the interferon regulatory factor family that binds to the
interferon-stimulated response element and activates expression of inter-
feron-induced genes. Proc. Natl. Acad. Sci. USA 92, 11657–11661.
Basagoudanavar, S.H., Thapa, R.J., Nogusa, S., Wang, J., Beg, A.A., and Ba-
lachandran, S. (2011). Distinct roles for the NF-kappa B RelA subunit during
antiviral innate immune responses. J. Virol. 85, 2599–2610.
Baum, A., and Garcı´a-Sastre, A. (2011). Differential recognition of viral RNA by
RIG-I. Virulence 2, 166–169.
Blonska,M., Shambharkar, P.B., Kobayashi, M., Zhang, D., Sakurai, H., Su, B.,
and Lin, X. (2005). TAK1 is recruited to the tumor necrosis factor-alpha (TNF-
alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent
manner and cooperates with MEKK3 leading to NF-kappaB activation.
J. Biol. Chem. 280, 43056–43063.
Blonska, M., Pappu, B.P., Matsumoto, R., Li, H., Su, B., Wang, D., and Lin, X.
(2007). The CARMA1-Bcl10 signaling complex selectively regulates JNK2 ki-
nase in the T cell receptor-signaling pathway. Immunity 26, 55–66.
Chiaretti, A., Pulitano`, S., Barone, G., Ferrara, P., Romano, V., Capozzi, D., and
Riccardi, R. (2013). IL-1 b and IL-6 upregulation in children with H1N1 influenza
virus infection. Mediators Inflamm. 2013, 495848.
Dienz, O., Rud, J.G., Eaton, S.M., Lanthier, P.A., Burg, E., Drew, A., Bunn, J.,
Suratt, B.T., Haynes, L., and Rincon, M. (2012). Essential role of IL-6 in protec-
tion against H1N1 influenza virus by promoting neutrophil survival in the lung.
Mucosal Immunol. 5, 258–266.
Ferris, M.T., Aylor, D.L., Bottomly, D., Whitmore, A.C., Aicher, L.D., Bell, T.A.,
Bradel-Tretheway, B., Bryan, J.T., Buus, R.J., Gralinski, L.E., et al. (2013).2400 Cell Reports 14, 2389–2401, March 15, 2016 ª2016 The AuthorModeling host genetic regulation of influenza pathogenesis in the collaborative
cross. PLoS Pathog. 9, e1003196.
Fitzgerald, K.A., McWhirter, S.M., Faia, K.L., Rowe, D.C., Latz, E., Golenbock,
D.T., Coyle, A.J., Liao, S.M., and Maniatis, T. (2003). IKKepsilon and TBK1 are
essential components of the IRF3 signaling pathway. Nat. Immunol. 4,
491–496.
Friedman, C.S., O’Donnell, M.A., Legarda-Addison, D., Ng, A., Ca´rdenas,
W.B., Yount, J.S., Moran, T.M., Basler, C.F., Komuro, A., Horvath, C.M.,
et al. (2008). The tumour suppressor CYLD is a negative regulator of RIG-I-
mediated antiviral response. EMBO Rep. 9, 930–936.
Gaide, O., Martinon, F., Micheau, O., Bonnet, D., Thome, M., and Tschopp, J.
(2001). Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10
phosphorylation and NF-kappaB activation. FEBS Lett. 496, 121–127.
Goubau, D., Schlee, M., Deddouche, S., Pruijssers, A.J., Zillinger, T., Goldeck,
M., Schuberth, C., Van der Veen, A.G., Fujimura, T., Rehwinkel, J., et al. (2014).
Antiviral immunity via RIG-I-mediated recognition of RNA bearing 50-diphos-
phates. Nature 514, 372–375.
Grabiner, B.C., Blonska, M., Lin, P.C., You, Y., Wang, D., Sun, J., Darnay, B.G.,
Dong, C., and Lin, X. (2007). CARMA3 deficiency abrogates G protein-coupled
receptor-induced NF-kappaB activation. Genes Dev. 21, 984–996.
Halfmann, R., and Lindquist, S. (2008). Screening for amyloid aggregation
by Semi-Denaturing Detergent-Agarose Gel Electrophoresis. J. Vis. Exp.
(17), 838.
He, L., L€uhrs, T., and Ritter, C. (2015). Solid-state NMR resonance assign-
ments of the filament-forming CARD domain of the innate immunity signaling
protein MAVS. Biomol. NMR Assign. 9, 223–227.
Hou, F., Sun, L., Zheng, H., Skaug, B., Jiang, Q.X., and Chen, Z.J. (2011).
MAVS forms functional prion-like aggregates to activate and propagate anti-
viral innate immune response. Cell 146, 448–461.
Janeway, C.A., Jr. (2013). Pillars article: approaching the asymptote? Evolu-
tion and revolution in immunology. Cold spring harb symp quant biol. 1989.
54: 1-13. J. Immunol. 191, 4475–4487.
Jiang, C., and Lin, X. (2012). Regulation of NF-kBby the CARD proteins. Immu-
nol. Rev. 246, 141–153.
Jiang, F., Ramanathan, A., Miller, M.T., Tang, G.Q., Gale, M., Jr., Patel, S.S.,
and Marcotrigiano, J. (2011a). Structural basis of RNA recognition and activa-
tion by innate immune receptor RIG-I. Nature 479, 423–427.
Jiang, T., Grabiner, B., Zhu, Y., Jiang, C., Li, H., You, Y., Lang, J., Hung, M.C.,
and Lin, X. (2011b). CARMA3 is crucial for EGFR-Induced activation of NF-kB
and tumor progression. Cancer Res. 71, 2183–2192.
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K.,
Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., et al. (2006). Differential roles of
MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441,
101–105.
Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K.J.,
Takeuchi, O., and Akira, S. (2005). IPS-1, an adaptor triggering RIG-I- and
Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981–988.
Klemm, S., Zimmermann, S., Peschel, C., Mak, T.W., and Ruland, J. (2007).
Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation
and cytokine production. Proc. Natl. Acad. Sci. USA 104, 134–138.
Liu, F., and Gu, J. (2011). Retinoic acid inducible gene-I, more than a virus
sensor. Protein Cell 2, 351–357.
Liu, S., Chen, J., Cai, X., Wu, J., Chen, X., Wu, Y.T., Sun, L., and Chen, Z.J.
(2013). MAVS recruits multiple ubiquitin E3 ligases to activate antiviral
signaling cascades. eLife 2, e00785.
Maelfait, J., Roose, K., Bogaert, P., Sze, M., Saelens, X., Pasparakis, M., Car-
pentier, I., van Loo, G., and Beyaert, R. (2012). A20 (Tnfaip3) deficiency in
myeloid cells protects against influenza A virus infection. PLoS Pathog. 8,
e1002570.
McAllister-Lucas, L.M., Ruland, J., Siu, K., Jin, X., Gu, S., Kim, D.S., Kuffa, P.,
Kohrt, D., Mak, T.W., Nun˜ez, G., and Lucas, P.C. (2007). CARMA3/Bcl10/
MALT1-dependent NF-kappaB activation mediates angiotensin II-responsives
inflammatory signaling in nonimmune cells. Proc. Natl. Acad. Sci. USA 104,
139–144.
McCartney, S.A., Thackray, L.B., Gitlin, L., Gilfillan, S., Virgin, H.W., and Co-
lonna, M. (2008). MDA-5 recognition of a murine norovirus. PLoS Pathog. 4,
e1000108.
Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschl-
ager, R., and Tschopp, J. (2005). Cardif is an adaptor protein in the RIG-I anti-
viral pathway and is targeted by hepatitis C virus. Nature 437, 1167–1172.
Moresco, E.M., Vine, D.L., and Beutler, B. (2011). Prion-like behavior of MAVS
in RIG-I signaling. Cell Res. 21, 1643–1645.
Pan, D., and Lin, X. (2013). Epithelial growth factor receptor-activated nuclear
factor kB signaling and its role in epithelial growth factor receptor-associated
tumors. Cancer J. 19, 461–467.
Parvatiyar, K., Barber, G.N., and Harhaj, E.W. (2010). TAX1BP1 and A20 inhibit
antiviral signaling by targeting TBK1-IKKi kinases. J. Biol. Chem. 285, 14999–
15009.
Poeck, H., Bscheider, M., Gross, O., Finger, K., Roth, S., Rebsamen, M., Han-
nesschla¨ger, N., Schlee, M., Rothenfusser, S., Barchet, W., et al. (2010).
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflam-
masome signaling for interleukin 1 beta production. Nat. Immunol. 11, 63–69.
Rasmussen, A.L., Okumura, A., Ferris, M.T., Green, R., Feldmann, F., Kelly,
S.M., Scott, D.P., Safronetz, D., Haddock, E., LaCasse, R., et al. (2014).
Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and
resistance. Science 346, 987–991.
Roth-Cross, J.K., Bender, S.J., and Weiss, S.R. (2008). Murine coronavirus
mouse hepatitis virus is recognized by MDA5 and induces type I interferon in
brain macrophages/microglia. J. Virol. 82, 9829–9838.
Saitoh, T., Yamamoto, M., Miyagishi, M., Taira, K., Nakanishi, M., Fujita, T.,
Akira, S., Yamamoto, N., and Yamaoka, S. (2005). A20 is a negative regulator
of IFN regulatory factor 3 signaling. J. Immunol. 174, 1507–1512.
Sankar, S., Chan, H., Romanow, W.J., Li, J., and Bates, R.J. (2006). IKK-i sig-
nals through IRF3 and NFkappaB to mediate the production of inflammatory
cytokines. Cell. Signal. 18, 982–993.CellSchafer, S.L., Lin, R., Moore, P.A., Hiscott, J., and Pitha, P.M. (1998). Regula-
tion of type I interferon gene expression by interferon regulatory factor-3.
J. Biol. Chem. 273, 2714–2720.
Seth, R.B., Sun, L., Ea, C.K., and Chen, Z.J. (2005). Identification and charac-
terization of MAVS, a mitochondrial antiviral signaling protein that activates
NF-kappaB and IRF 3. Cell 122, 669–682.
Sun, J., and Lin, X. (2008). Beta-arrestin 2 is required for lysophosphatidic
acid-induced NF-kappaB activation. Proc. Natl. Acad. Sci. USA 105, 17085–
17090.
Sun, F., Zhang, Y.B., Liu, T.K., Gan, L., Yu, F.F., Liu, Y., and Gui, J.F. (2010).
Characterization of fish IRF3 as an IFN-inducible protein reveals evolving regu-
lation of IFN response in vertebrates. J. Immunol. 185, 7573–7582.
Wang, D., You, Y., Lin, P.C., Xue, L., Morris, S.W., Zeng, H., Wen, R., and Lin,
X. (2007a). Bcl10 plays a critical role in NF-kappaB activation induced by G
protein-coupled receptors. Proc. Natl. Acad. Sci. USA 104, 145–150.
Wang, X., Hussain, S., Wang, E.J., Wang, X., Li, M.O., Garcı´a-Sastre, A., and
Beg, A.A. (2007b). Lack of essential role of NF-kappa B p50, RelA, and cRel
subunits in virus-induced type 1 IFN expression. J. Immunol. 178, 6770–6776.
Wang, J., Basagoudanavar, S.H., Wang, X., Hopewell, E., Albrecht, R., Garcı´a-
Sastre, A., Balachandran, S., and Beg, A.A. (2010). NF-kappa B RelA subunit is
crucial for early IFN-beta expression and resistance to RNA virus replication.
J. Immunol. 185, 1720–1729.
Xu, L.G., Wang, Y.Y., Han, K.J., Li, L.Y., Zhai, Z., and Shu, H.B. (2005). VISA is
an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 19,
727–740.
Xu, H., He, X., Zheng, H., Huang, L.J., Hou, F., Yu, Z., de la Cruz, M.J., Borkow-
ski, B., Zhang, X., Chen, Z.J., and Jiang, Q.X. (2014). Structural basis for the
prion-like MAVS filaments in antiviral innate immunity. eLife 3, e01489.
Zhao, T., Yang, L., Sun, Q., Arguello, M., Ballard, D.W., Hiscott, J., and Lin, R.
(2007). The NEMO adaptor bridges the nuclear factor-kappaB and interferon
regulatory factor signaling pathways. Nat. Immunol. 8, 592–600.
Zhong, B., Yang, Y., Li, S., Wang, Y.Y., Li, Y., Diao, F., Lei, C., He, X., Zhang, L.,
Tien, P., and Shu, H.B. (2008). The adaptor protein MITA links virus-sensing re-
ceptors to IRF3 transcription factor activation. Immunity 29, 538–550.Reports 14, 2389–2401, March 15, 2016 ª2016 The Authors 2401
